Showing 2521-2530 of 3570 results for "".
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technolog
- Warts and All: Novan Files Chapter 11, Sells Assetshttps://practicaldermatology.com/news/warts-and-all-novan-files-chapter-11-sells-assets/2461870/Novan is selling all of its assets, including Berdazimer Gel, 10.3% (SB206), and has filed for Chapter 11 Protection. The Company entered into a stalking horse asset purchase agreement (APA) with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief unde
- Revian Red Hair Growth System Takes on CCCA in Second Studyhttps://practicaldermatology.com/news/revian-red-hair-growth-system-takes-on-ccca-in-second-study/2461864/Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wirel
- Cetuximab Plus Radiation May Be Effective Treatment for Advanced Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/cetuximab-plus-radiation-may-be-effective-treatment-for-advanced-squamous-cell-skin-cancer/2461860/Cetuximab plus radiotherapy may be an effective treatment option for locally advanced cutaneous squamous cell cancers (laCSCC), with manageable toxicity, according to a study in Oncotarget. Cetuximab is
- Biosimilar Update: FDA Accepts Dr. Reddy’s Proposed Rituximab Biosimilar Application for Reviewhttps://practicaldermatology.com/news/biosimilar-update-fda-accepts-dr-reddys-proposed-rituximab-biosimilar-application-for-review/2461859/Dr. Reddy’s Laboratories Ltd’s Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (FDA). This closely follows acceptance of its rituximab biosimi
- Opzelura Cream Safely Eases AD in Young Kidshttps://practicaldermatology.com/news/opzelura-cream-safely-eases-ad-in-young-kids/2461857/Incyte’s ruxolitinib cream (Opzelura) cleared skin in significantly more kids with atopic dermatitis (AD) than a nonmedicated topical control, a new study shows. The study, which included 300 kids aged ≥2 to <12, met its primary endpoint and showed signi
- Fecal Transplants Show Promise in Improving Response to Immunotherapy in Melanoma Patientshttps://practicaldermatology.com/news/fecal-transplants-show-promise-in-improving-response-to-immunotherapy-in-melanoma-patients/2461849/Fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma, according to research in Nature Medicine. Preliminar
- NY Dermatologist Louise Kaufmann, MD, Wins an International Award for Social Responsibility in Dermatology from L’Oréal and ILDShttps://practicaldermatology.com/news/dr-louise-kaufmann-wins-an-international-awards-for-social-responsibility-in-dermatology-from-loreal-and-ilds/2461842/Louise Kaufmann, MD, a general and cosmetic dermatologist in Great Neck, New York, took home an International Award for Social Responsibility in Dermatology for her efforts to provide access to dermatological care in rural and underserved areas of Jamaica. The awards, sp
- MHRA Grants Marketing Authorization for Incyte's Opzelura Cream for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescentshttps://practicaldermatology.com/news/mhra-grants-marketing-authorization-for-incytes-opzelura-cream-for-non-segmental-vitiligo-with-facial-involvement-in-adults-and-adolescents/2461838/The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing clearance for Incyte’s Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “Today&rs
- Dr. Uri Geiger Named Chairman of its Board of Directors at STRATA Skin Scienceshttps://practicaldermatology.com/news/dr-uri-geiger-named-chairman-of-its-board-of-directors-at-strata-skin-sciences/2461837/Uri Geiger, PhD, is the new Chairman of the Board of Directors at STRATA Skin Sciences. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation.